PERORAL DABIGATRAN ETEXILATE PHARMACEUTICAL COMPOSITIONS Russian patent published in 2017 - IPC A61K9/16 A61K9/50 A61K31/4439 A61P7/02 

FIELD: pharmacology.

SUBSTANCE: composition comprises particulate mix, where a) the first particulate type comprises the dabigatran etexilate in the form of the free base or in the form of its pharmaceutically acceptable salts, polymorphs, solvates or hydrates and which does not have acids; and b) the second particulate type comprises at a minimum one pharmaceutically acceptable organic acid, where at a minimum one particulate type is encased in an outer protection sheathe. The composition is destined for the reduction of the stroke and the systemic embolism risk in patients with the nonvalvular atrial fibrillation and/or for the preventive measures for the venous thromboembolic complication in adult patients that had a surgical operation on elective total hip replacement or the surgical operation on total knee arthroplasty.

EFFECT: implementation of the invention allows to get the composition, which differs by fast dissolution and significant bioactivation.

18 cl, 3 ex, 11 tbl